Tactile Medical (TCMD) Q2 2026: Lymphedema Revenue Grows 12% Amid Airway Clearance Inventory Challenges
Tactile Medical demonstrated solid top-line growth driven by its core lymphedema business despite a temporary setback in airway clearance sales due to inventory adjustments. The company’s strategic investments in product innovation and market expansion underpin its confidence in sustainable growth. Updated guidance reflects cautious airway clearance expectations balanced by robust lymphedema momentum and emerging diagnostic capabilities.
Summary
- Core Business Resilience: Lymphedema product line maintains strong growth despite external reimbursement and inventory pressures.
- Strategic Portfolio Expansion: New distribution agreements and diagnostic platform development broaden patient reach and treatment options.
- Operational Discipline: Margin expansion and adjusted EBITDA growth demonstrate effective cost management alongside growth investments.
Business Overview
Tactile Medical is a medical technology company specializing in at-home therapies for chronic conditions such as lymphedema and respiratory disorders. The company generates revenue primarily through sales and rentals of its lymphedema product line, including FlexiTouch and Lymphatec, and its airway clearance product line, notably the AfloVest system. The lymphedema segment represents approximately 86% of total revenue, underscoring its central role in the business model.
Performance Analysis
In the second quarter of 2026, Tactile Medical reported total revenue of $85.7 million, representing a 9% year-over-year increase. The lymphedema product line drove this growth with a 12% rise in sales and rentals to $73.6 million, reflecting strong referral trends, improved territory productivity, and favorable Medicare coverage adjustments. Conversely, the airway clearance segment experienced a 7% decline to $12.1 million, primarily due to temporary inventory management among key durable medical equipment (DME) partners following the launch of the next-generation AfloVest system.
Gross margin expanded by 180 basis points to 76%, driven by lower manufacturing costs and favorable product mix. Operating expenses increased 7% to $58.5 million, reflecting strategic investments in commercial capabilities, technology, and reimbursement functions. Despite these investments, operating income rose 67% to $6.8 million, and net income more than doubled to $7.8 million, supported by an income tax benefit. Adjusted EBITDA grew 49% to $11.4 million, underscoring disciplined expense management alongside revenue growth.
- Lymphedema Growth Drivers: Medicare National Coverage Determination (NCD) alignment and expanded sales force productivity underpin durable demand.
- Airway Clearance Inventory Impact: Elevated inventory levels at select large DMEs delayed orders, expected to normalize in Q4 2026.
- Margin and Profitability Expansion: Improved gross margins and leverage on operating expenses contribute to significant profitability gains.
The company’s balance sheet remains robust with $69.9 million in cash and no debt, enabling continued investments in growth and shareholder returns, including $5.3 million in share repurchases during the quarter.
Executive Commentary
"We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion… Our core lymphedema business remains healthy and our view of the long-term opportunity for AfloVest is unchanged despite the temporary inventory management dynamic."
Sheri Dodd, Chief Executive Officer
"Revenue and profitability exceeded our expectations during the quarter driven by continued strength in our lymphedema business and disciplined execution… Operating expenses reflected continued strategic investments to support long-term growth, including investments in our commercial organization, technology initiatives, and operational capabilities."
Elaine Birkemeyer, Chief Financial Officer
Strategic Positioning
1. Strengthening Lymphedema Market Leadership
Tactile Medical’s lymphedema segment benefits from a diversified payer mix, including Medicare, commercial insurers, and the Department of Veterans Affairs (VA). The company’s alignment with Medicare’s stable NCD policy has facilitated increased FlexiTouch adoption, particularly among Medicare patients. Despite the introduction of prior authorization requirements in April 2026, Tactile’s proactive operational preparation and ongoing payer engagement have mitigated order disruptions, supporting sustained growth momentum.
2. Airway Clearance Product Innovation and Inventory Management
The launch of the next-generation AfloVest system introduced temporary inventory management challenges among a few large DME partners, leading to a 7% decline in airway clearance sales for the quarter. However, the new product’s enhanced features—including size adjustability, reduced weight, untethered design, and connectivity—position it strongly for future demand recovery. Management expects ordering patterns to normalize in the fourth quarter as inventory levels rebalance.
3. Expanding Diagnostic and Treatment Capabilities through Lymphatec
The acquisition and integration of Lymphatec advance Tactile Medical’s strategy to address unmet needs in early diagnosis and personalized therapy for lymphedema. The FDA-cleared Lymphatec platform provides objective, quantitative limb volume assessments and 3D anatomical modeling, improving disease monitoring. The company is pursuing an expanded diagnostic indication with expected FDA approval in 2027 and a Category 3 CPT reimbursement code, which would facilitate broader clinical adoption and payer coverage.
4. Broadening Patient Reach via Strategic Partnerships
Tactile Medical secured an exclusive U.S. distribution agreement with Elastomed to market the MyoSleeve wearable compression device to veterans, active-duty service members, and dependents through the Department of Defense and VA channels. This non-pneumatic, discreet device complements the company’s pneumatic compression portfolio by addressing earlier-stage chronic swelling patients, enhancing therapy adherence and expanding addressable markets within the VA ecosystem.
5. Operational Excellence and Technology Integration
The company continues to invest in AI-driven operational improvements aimed at reducing administrative friction in the order management process, particularly related to Medicare prior authorization workflows. These technology initiatives support improved efficiency, faster access to therapy for patients, and operating leverage. The sales organization remains stable, with a focus on optimizing territory productivity and leveraging CRM tools to enhance referral growth and patient engagement.
Key Considerations
Tactile Medical’s Q2 2026 results reflect a business successfully navigating near-term headwinds while investing for long-term growth. Key considerations for investors include:
- Medicare Prior Authorization Impact: The April 2026 introduction of prior authorization for Medicare patients created initial order timing delays, expected to moderate as operational familiarity improves.
- Inventory Dynamics in Airway Clearance: Temporary elevated inventory at select large DMEs has suppressed short-term sales but is anticipated to normalize by Q4, enabling revenue recovery.
- Growth Potential of Lymphatec: While currently a modest revenue contributor, Lymphatec’s diagnostic expansion and reimbursement initiatives represent a strategic growth lever in the lymphedema care continuum.
- Leveraging Established VA Relationships: The MyoSleeve distribution agreement leverages Tactile Medical’s existing VA infrastructure, minimizing incremental operating expenses while expanding treatment options.
- Capital Allocation Balance: The company maintains a disciplined approach, balancing strategic investments, share repurchases, and cash preservation to support flexibility.
Risks
Risks include potential delays in payer policy changes, particularly regarding commercial coverage for head and neck lymphedema therapies, and the pace of inventory normalization in the airway clearance channel. Supply chain disruptions or competitive pressures could also impact future product adoption. Additionally, execution risks remain around the integration and commercialization of new diagnostic and treatment platforms.
Forward Outlook
For the third quarter of 2026, management anticipates continued revenue strength in the lymphedema segment and ongoing airway clearance inventory adjustments. The company expects a sequential growth increase in Q3 driven by normalization of Medicare prior authorization impacts and anticipates airway clearance ordering patterns to begin recovering in Q4.
- Full year 2026 revenue guidance updated to $360 million to $366 million, reflecting 9% to 11% growth year-over-year.
- Lymphedema revenue expected to grow in the low double-digit range; airway clearance revenue projected to be approximately flat year-over-year.
Management continues to forecast adjusted EBITDA in the range of $49 million to $51 million, balancing growth investments with operational discipline.
Takeaways
Tactile Medical’s Q2 results illustrate a company with a solid core business and a clear strategic roadmap. Key takeaways for investors include:
- Resilient Lymphedema Franchise: Sustained 12% growth driven by favorable payer policies and effective sales execution highlights the strength of the core business.
- Temporary Airway Clearance Setback: Inventory management following a next-generation product launch caused short-term sales softness but is well understood and expected to resolve by year-end.
- Strategic Portfolio Expansion: Investments in diagnostics, new product introductions, and VA partnerships position the company for broader market penetration and long-term growth.
Conclusion
Tactile Medical’s second quarter performance confirms the durability of its lymphedema business while managing transient airway clearance channel challenges. The company’s strategic initiatives in diagnostics and expanded treatment options, coupled with operational improvements, provide a solid foundation for sustainable, profitable growth. Updated guidance reflects a balanced view, maintaining confidence in the core while prudently addressing near-term dynamics.
Industry Read-Through
Tactile Medical’s experience underscores the complexities faced by medical device companies in managing product transitions within durable medical equipment distribution channels. The temporary inventory adjustments highlight the importance of visibility and collaboration with key partners. Moreover, the company’s focus on expanding diagnostic capabilities and payer engagement offers a blueprint for others in the chronic care segment seeking to broaden patient access and reimbursement. The integration of AI in operational workflows signals a growing trend towards technology-enabled efficiency in healthcare delivery.